

## Nomination Committee appointed ahead of AGM 2023 in SynAct Pharma AB

**SynAct Pharma AB (publ) ("SynAct") today announced that the Nomination Committee in preparation for the Annual General Meeting (AGM) 2023 on May 25, 2023, has been appointed.**

Pursuant to the instruction and charter for the Nomination Committee adopted at the AGM held on May 21, 2021, the Nomination Committee shall consist of four members, representing the three largest shareholders as per end of September, together with the chairman of the Board of Directors.

Based on the above, the Nomination Committee for the AGM 2023 has been established to consist of the following persons:

- Niels Ankerstjerne Sloth, appointed by Bioinvest ApS
- Jens Bager, appointed by GL Capital AB
- Steen Christensen, appointed by Next Stage Ventures ApS
- Torbjørn Bjerke, Chairman of the Board of Directors

Jens Bager has been appointed chairman of the Nomination Committee. In total, the Nomination Committee represents ~20% of the total number of shares and votes in the company.

The Nomination Committee's tasks for the AGM 2023 are to propose a Chairman for the AGM, members of the Board of Directors and Chairman of the Board of Directors as well as auditor. The Nomination Committee will also propose remuneration to members and the Chairman of the Board of Directors as well as proposal for remuneration of the auditor. Finally, the Nomination Committee will propose principles for appointing the Nomination Committee (if the Nomination Committee considers that the current principles and instructions should be updated).

Shareholders are welcome to submit their proposals and views to the Nomination Committee to SynAct Pharma AB, Att: Nomination Committee, c/o Medicon Village, Scheelevägen 2, 223 63 Lund, or by e-mail to [valberedning@synactpharma.com](mailto:valberedning@synactpharma.com). To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than January 31, 2023.

The Nomination Committee's proposals will be announced in the notice for the AGM 2023 and on SynAct's web site.

*The information was submitted, through the agency of the contact person below, for publication at 3.00 pm (CEST) on October 21, 2022.*

**For further information about SynAct Pharma AB, please contact:**

**Jeppe Øvlesen**

CEO, SynAct Pharma AB

Phone: +45 28 44 75 67

Mail: [joo@synactpharma.com](mailto:joo@synactpharma.com)

**Patrik Renblad**

CFO, SynAct Pharma AB

Phone: +46 707 47 97 68

Mail: [par@synactpharma.com](mailto:par@synactpharma.com)

**About SynAct Pharma AB**

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: [www.synactpharma.com](http://www.synactpharma.com).

**Attachments**

[Nomination Committee appointed ahead of AGM 2023 in SynAct Pharma AB](#)